According to the drug price regulator, the moving annual turnover (MAT) for consumers on formulations for which the new prices have been finalised until the end of March 2023 is estimated to have decreased by over Rs. 3,500 crore annually…
Tag: Price control
Under the 2013 revisions to Schedule I of the Drugs (Prices Control) Order, the National Pharmaceutical Pricing Authority (NPPA) has released the draught version of the ceiling price calculation for 20 formulations, including specific strengths of paracetamol, povidone iodine, risperidone…
After taking into account the arguments made by Sanofi India Ltd, the Organization of Pharmaceutical Producers of India (OPPI), and the US-India Strategic Partnership Forum, the National Pharmaceutical Pricing Authority (NPPA) has established separate ceiling prices for insulin glargine 100…
In line with its efforts to revise the ceiling price of formulations under the revised Schedule I of the Drugs (Prices Control) Order, 2013, which was amended last year with the National List of Essential Medicines (NLEM), 2022, the National…
